The infantile hemangioma market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 3.2% in the above-mentioned research forecast period. Increase in research and development related to the treatment of infantile hemangioma can drive the infantile hemangioma market growth. The incidence of the infantile hemangioma is 4-5% and rise in prevalence of hemangioma mainly in non-hispanic white female babies may drive the infantile hemangioma market growth. Different therapeutic regimens such as oral, injectables and topical medications in combination with the treatments such as laser, surgical and observational treatment drives the infantile hemangioma market. Moreover, the discovery of new treatments as well as new drugs for the treatment of IH may increase the market growth for the infantile hemangioma. In addition, increase in awareness programs about the infantile hemangioma increases the infantile hemangioma market growth. For instance, American Academy of Pediatrics has organized an awareness programs through webinar. But the side-effects related to treatment, poor efficacy rate and high cost of therapies may hamper the growth of infantile hemangioma market. One of the challenges for the infantile hemangioma market is stringent approval policies for new therapies. Similarly, the management of IH differ from patient to patient and adequate knowledge about the treatment mode is a challenging task for the physicians.
Market Analysis and Insights
Infantile hemangioma (IH) is the most common type of vascular tumors. It mainly occurs in 5% of infants making them the most common benign tumour. In this, the blood vessels get scrambled or form a cluster in or under the skin of baby. It occurs when there is a proliferation of both vascular and endothelial cells that is distributed on face, head and neck. It becomes visible in first few days to weeks after the birth of the baby. There are two different types of IH that is superficial hemangiomas that grows on the surface of the skin and the other one is deep hemangiomas that grow under the skin. Sometimes, the hemangioma grows inside the organs such as kidney, liver or brain that cannot be seen at the early stage of the birth. In most of the cases, IH is harmless and disappears at the age of 5 months or 1 year. But in some patient population, the IH leaves the permanent scar, disfigurement and causes pain, bleeding, ulceration which needs a personal attention and treatment.
Get Your Sample Today: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-infantile-hemangioma-market
Infantile Hemangioma Market Scope
The infantile hemangioma market is segmented on the basis of treatment type, drug type, route of administration, diagnosis, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment type, the infantile hemangioma market is segmented into medication, surgery and laser treatment
- On the basis of drug type, the infantile hemangioma market is segmented into beta-blockers and steroids. Beta-blockers are further segmented to propranolol, timolol, atenolol, nadolol whereas steroids are sub-segmented to methylprednisolone, prednisolone and triamcinolone.
- On the basis of route of administration, the infantile hemangioma market is segmented into oral, injectablesand others.
- On the basis of diagnosis, the infantile hemangioma market is segmented into X-ray, computerized tomography (CT) scans, biopsy, angiogram and others.
- On the basis of end-user, the infantile hemangioma market is segmented into hospitals, homecare, specialty clinics and others
- On the basis of distribution channel, the infantile hemangioma market has also been segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.
Infantile Hemangioma Market Country Level Analysis
On geographical estimation, North America accounts the largest market share due to rise in healthcare expenditure and due to availability of advanced treatments and products. The infantile hemangioma market players are mainly from the region which makes the largest market share. Europe accounts the second largest market share due to increased cases of infantile hemangioma and high government support for research and development of novel drugs.
The countries covered in the infantile hemangioma market report are
- the U.S., Canada,
- Mexico in North America,
- Brazil, Argentina,
- Peru, Rest of South America, as part of South America,
- Germany, France, U.K.,
- Netherlands, Switzerland,
- Belgium, Russia, Italy,
- Spain, Turkey, Hungary,
- Lithuania, Austria, Ireland,
- Norway, Poland, Rest of Europe in Europe,
- China, Japan,
- India, South Korea, Singapore,
- Malaysia, Australia,
- Thailand, Indonesia, Philippines,
- Vietnam, Rest of Asia-Pacific,
- Saudi Arabia, U.A.E,
- Egypt, Israel, Kuwait, South Africa,
- Rest of Middle East and Africa, as a part of Middle East and Africa.
Browse The Table of Contents And List of Figures: https://www.databridgemarketresearch.com/toc/?dbmr=global-infantile-hemangioma-market
Major TOC of the Infantile Hemangioma Market Report
Chapter One:
MARKET SEGEMENTATION
EXECUTIVE SUMMARY
PREMIUM INSIGHTS
MARKET OVERVIEW
Buy Now Access Full Report:- https://www.databridgemarketresearch.com/reports/global-infantile-hemangioma-market
The countries covered in the Infantile Hemangioma Market report are
- S.,
- Canada,
- Mexico in North America,
- Brazil,
- Argentina,
- Peru,
- Rest of South America,
- as part of South America,
- Germany,
- France,
- K.,
- Netherlands,
- Switzerland,
- Belgium,
- Russia, Italy,
- Spain,
- Turkey,
- Hungary,
- Lithuania, Austria,
- Ireland, Norway,
- Poland, Rest of Europe in Europe,
- China, Japan,
- India, South Korea,
- Singapore, Malaysia,
- Australia, Thailand,
- Indonesia, Philippines,
- Vietnam, Rest of Asia-Pacific,
- Saudi Arabia, U.A.E,
- Egypt, Israel, Kuwait,
- South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
Competitive Landscape and Infantile Hemangioma Market Share Analysis
The infantile hemangioma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to infantile hemangioma market.
The major players covered in the infantile hemangioma market report are
- Pierre Fabre Group,
- BIOLASE, Inc.,
- Bausch Health,
- Cutera, Teva Pharmaceutical Industries Ltd.,
- IRIDEX Corporation,
- Alma Lasers Ltd,
- LINLINE Medical Systems Ltd.,
- Merck Co., Inc.,
- AbbVie Inc., ALLERGAN,
- Akorn, Pfizer Inc.,
- AstraZeneca among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Browse Related Reports@
Global Container Monitoring Market
Global Ophthalmic Sutures Market
Global alcohol-dependency treatment market
Global Chronic Obstructive Pulmonary Disease (COPD) Drug Market
Global Cancer Supportive Care Drugs Market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best Market opportunities and foster efficient information for your business to thrive in the Market
Contact:
Data Bridge Market Research
Tel: +1-888-3895-2818
